NORD-STAR results. Biologic + MTX combo seemed better than slightly strange "conventional"(ACT) group of MTX + oral steroids or triple therapy + IA injections @RheumNow #EULAR2022 OP0058 https://t.co/tOfTlcplFR https://t.co/CvtvuVn5Xj

• EULAR Abstract Archive

#EULAR2022 POS0235: Filgotinib Safety in RA for Median 2.2 years: ▶️No new safety concerns from 2020 report with shorter f/u ▶️Adverse events stable, or decreased, from early studies @Rheumnow https://t.co/DO15Tqim4n

@Rheumnow #EULAR2022 POS0240 ▶️ In 2021, 73.6% of Belgian RA patients staring a JAKi, started a 2nd generation JAKi (UPA, FIL). Predictors for 1st generation usage (BAR, TOFA): older age, prior DMARD therapies. What would you start as a first JAKi?

Household Cleaning is dirty business at least if you have #rheumatoid #arthritis as silica exposure from laundry and cleaning products were associated with RA ILD. #EULAR opening day. #ClinicalPearl #EULAR2022 @RheumNow #OP0006 https://t.co/OJQMy9Fe9m

ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow

#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI

After the #EULAR2022 Recommendations session, it begs the question - Do we follow it? In Germany, the answer is sometimes Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD POS0234 @Rheumnow https://t.co/0DaP5b7Htc